Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years

Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.

pain killer stop headache migraine, no more suffering painkiller paracetamol aspirine merphine medicine treatment prevention and therapy
Acute treatments are used to stop migraines when they occur • Source: Shutterstock

Migraine impacts a billion people globally, including about 39 million patients in the US alone, representing a very large market that still has a lot of unmet needs despite the availability of well-known generic drugs for both prevention and acute treatment. And while three new preventive therapies launched in the US in 2018, three new acute migraine treatments may reach the market in early 2020.

[Sidebar#SC141522]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Market Snapshot

More from Scrip